Indivior PLC (NASDAQ:INDV) Shares Purchased by Melqart Asset Management UK Ltd

Melqart Asset Management UK Ltd boosted its position in shares of Indivior PLC (NASDAQ:INDV) by 675.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 104,790 shares of the company’s stock after acquiring an additional 91,280 shares during the quarter. Melqart Asset Management UK Ltd’s holdings in Indivior were worth $1,303,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INDV. Rathbones Group PLC grew its holdings in Indivior by 11.6% in the fourth quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock valued at $183,000 after purchasing an additional 1,483 shares during the last quarter. Stifel Financial Corp grew its stake in Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after acquiring an additional 2,450 shares during the last quarter. Clark Estates Inc. NY increased its holdings in Indivior by 1.3% during the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company’s stock valued at $3,199,000 after acquiring an additional 3,300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Indivior during the fourth quarter worth about $56,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Indivior by 7.7% in the third quarter. Geode Capital Management LLC now owns 132,239 shares of the company’s stock valued at $1,289,000 after purchasing an additional 9,500 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Trading Up 7.4 %

Shares of NASDAQ INDV opened at $11.56 on Friday. The stock has a fifty day moving average price of $9.48 and a 200 day moving average price of $10.32. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $18.59. The company has a market cap of $1.59 billion, a P/E ratio of -33.03 and a beta of 0.93.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. On average, sell-side analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on INDV. Piper Sandler dropped their price target on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw initiated coverage on shares of Indivior in a report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price on the stock.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.